What is the difference between Retatrutide and Cagrilintide?

Retatrutide (Retatrutide (LY3437943)) is graded A and is Not FDA-approved — Phase 3 trials (TRIUMPH program) for obesity. Cagrilintide (Cagrilintide (long-acting amylin analog)) is graded A and is Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress. They are commonly compared because they share the categories: weight-loss, metabolic.

Which has stronger clinical evidence — Retatrutide or Cagrilintide?

On our internal evidence scale, Retatrutide is A and Cagrilintide is A. A+ indicates large RCTs plus FDA approval; C indicates primarily preclinical or anecdotal evidence.

What is the typical dose of Retatrutide vs Cagrilintide?

Retatrutide: Trial range: 1–12 mg weekly (subcutaneous). Cagrilintide: Trial range: 0.16–4.5 mg weekly (subcutaneous). Always work with a licensed clinician — peptide dosing should be individualized.

Retatrutide vs Cagrilintide

Both Retatrutide and Cagrilintide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Retatrutide

Evidence A

Retatrutide (LY3437943)

Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.

View full Retatrutide profile →

Cagrilintide

Evidence A

Cagrilintide (long-acting amylin analog)

A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.

View full Cagrilintide profile →

Side-by-Side

Attribute	Retatrutide	Cagrilintide
Evidence Grade	A	A
FDA Status	Not FDA-approved — Phase 3 trials (TRIUMPH program) for obesity	Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress
Typical Dose	Trial range: 1–12 mg weekly (subcutaneous)	Trial range: 0.16–4.5 mg weekly (subcutaneous)
Clinics Indexed	12	8
Categories	weight-loss, metabolic	weight-loss, metabolic

Key reported benefits — Retatrutide

✓Highest reported weight loss
✓Triple incretin/glucagon mechanism
✓Metabolic improvement

Key reported benefits — Cagrilintide

✓Amylin pathway weight loss
✓Synergy with GLP-1
✓Lower-dose tolerability

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons